Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News archive
Showing 1040 results
June 2015
-
Media ReleaseNovartis drug Arzerra® improved median progression-free survival by 54% in patients with relapsed chronic lymphocytic leukemiaArzerra significantly improved PFS when added to fludarabine + cyclophosphamide (median 28.9 mos vs 18.8 mos) after initial treatment stopped working Patients receiving Arzerra plus…
-
Media ReleaseNovartis reports new analysis showing Xolair® improving quality of life by 78% for chronic spontaneous urticaria patientsNew analysis from pivotal Phase III studies show Xolair® (omalizumab) significantly improved quality of life scores for Chronic Spontaneous Urticaria (CSU) patients compared to placebo[1],[2]…
-
Media ReleaseNovartis gains FDA approval for Promacta® providing new option for children, ages 6 and older, with chronic ITP, a rare blood disorderPromacta® (eltrombopag) significantly increased and sustained platelet counts in two studies, including the largest Phase III clinical trial in this patient population Characterized by a low…
-
Media ReleaseNovartis presents new data at WCD demonstrating significant efficacy of Cosentyx® in patients with psoriasis of the nails, palms and solesCosentyx (secukinumab) met the primary endpoints of superiority compared to placebo in patients with difficult-to-treat psoriasis of the nails, palms and soles[1],[2] One third of patients…
-
Media ReleaseNovartis announces new one-year results demonstrating sustained secukinumab efficacy in ankylosing spondylitis patients74% of patients in MEASURE 2 achieved clinically significant and sustained improvement in symptoms of ankylosing spondylitis (AS) with secukinumab 150 mg after one year of treatment[1] AS is…
-
Media ReleaseNovartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphomaData show adult patients may achieve durable response rates, with 13 of 19 evaluable patients with relapsed/refractory non-Hodgkin lymphomas responding to therapy[1] Recent milestones for…
-
Media ReleaseNovartis presents new data at ASCO for Zykadia® and combination of Tafinlar® and Mekinist® in certain NSCLC patients with unmet needsIn Phase II studies, Zykadia (ceritinib) shrank tumors in patients with ALK+ NSCLC; comparable overall response in those with or without brain metastases[1],[2] Tafinlar (dabrafenib) and…
May 2015
-
Media ReleaseCombination of Novartis drugs Tafinlar® and Mekinist® shows significant survival benefit in patients with metastatic melanomaFinal analysis of COMBI-d confirms overall survival benefit of combination therapy in patients with BRAF V600E/K mutation-positive metastatic melanoma Tafinlar and Mekinist in combination…
-
Media ReleaseNovartis presents new data on 21 medicines and 11 investigational compounds at ASCO and EHAOverall survival data for Tafinlar® and Mekinist® combination to be presented in metastatic BRAF V600E/K mutation-positive cutaneous melanoma New data for Zykadia® in ALK+ non-small cell…
-
Media ReleaseNovartis drug Afinitor® extended progression-free survival in Phase III trial in advanced gastrointestinal or lung neuroendocrine tumorsStudy in patients with advanced nonfunctional neuroendocrine tumors (NET) of gastrointestinal (GI) or lung origin met primary endpoint[1] Full results will be submitted for presentation at…
-
Media ReleaseNovartis announces two positive US phase III programs in COPD for QVA149 and NVA237QVA149 improved lung function, breathlessness and health-related quality of life in moderate-to-severe COPD patients, according to EXPEDITION trial results[1]-[7] GEM 1 & 2 studies…
-
Media ReleaseNovartis lung cancer drug Zykadia® gains EU approval, providing new therapy for certain patients with ALK+ NSCLCZykadia (ceritinib) is the first treatment option approved for patients in Europe with ALK+ NSCLC previously treated with the ALK inhibitor crizotinib Marketing authorization was based on…